173 related articles for article (PubMed ID: 20609181)
1. Screening and analysis of adsorbents for pemphigus autoantibodies.
Yamada H; Itoh A; Hatanaka Y; Tsukiji M; Takamori K
Ther Apher Dial; 2010 Jun; 14(3):292-7. PubMed ID: 20609181
[TBL] [Abstract][Full Text] [Related]
2. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
4. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
5. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development?
Torzecka JD; Woźniak K; Kowalewski C; Waszczykowska E; Sysa-Jedrzejowska A; Pas HH; Narbutt J
Arch Dermatol Res; 2007 Aug; 299(5-6):239-43. PubMed ID: 17534636
[TBL] [Abstract][Full Text] [Related]
6. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins.
Langenhan J; Dworschak J; Saschenbrecker S; Komorowski L; Schlumberger W; Stöcker W; Westermann J; Recke A; Zillikens D; Schmidt E; Probst C
Exp Dermatol; 2014 Apr; 23(4):253-9. PubMed ID: 24533885
[TBL] [Abstract][Full Text] [Related]
7. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
8. The mapping of linear B-cell epitope regions in the extracellular parts of the desmoglein 1 and 3 proteins: recognition of immobilized peptides by pemphigus patients' serum autoantibodies.
Szabados H; Bősze S; Silló P; Kárpáti S; Hudecz F; Uray K
J Pept Sci; 2013 Feb; 19(2):84-94. PubMed ID: 23297065
[TBL] [Abstract][Full Text] [Related]
9. Recalcitrant facial pemphigus vulgaris: correlation of skin lesions with the ratio of antidesmoglein antibodies 1 and 3.
Fujii M; Honma M; Iinuma S; Kaneta K; Komatsu S; Sato K; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Apr; 36(3):284-7. PubMed ID: 21418270
[TBL] [Abstract][Full Text] [Related]
10. Immunoadsorption in pemphigus.
Eming R; Hertl M
Autoimmunity; 2006 Nov; 39(7):609-16. PubMed ID: 17101505
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
Amagai M; Nishikawa T; Nousari HC; Anhalt GJ; Hashimoto T
J Clin Invest; 1998 Aug; 102(4):775-82. PubMed ID: 9710446
[TBL] [Abstract][Full Text] [Related]
12. Herpetiform pemphigus without anti-desmoglein 1/3 autoantibodies.
Nakashima H; Fujimoto M; Watanabe R; Ishiura N; Yamamoto AI; Hashimoto T; Tamaki K
J Dermatol; 2010 Mar; 37(3):264-8. PubMed ID: 20507392
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
Green MG; Bystryn JC
Arch Dermatol; 2008 Dec; 144(12):1621-4. PubMed ID: 19075146
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.
Nagel A; Lang A; Engel D; Podstawa E; Hunzelmann N; de Pita O; Borradori L; Uter W; Hertl M
Clin Immunol; 2010 Mar; 134(3):320-30. PubMed ID: 20015693
[TBL] [Abstract][Full Text] [Related]
15. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
16. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
17. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.
Nguyen VT; Ndoye A; Bassler KD; Shultz LD; Shields MC; Ruben BS; Webber RJ; Pittelkow MR; Lynch PJ; Grando SA
Arch Dermatol; 2001 Feb; 137(2):193-206. PubMed ID: 11176692
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris.
Lo AS; Mao X; Mukherjee EM; Ellebrecht CT; Yu X; Posner MR; Payne AS; Cavacini LA
PLoS One; 2016; 11(6):e0156800. PubMed ID: 27304671
[TBL] [Abstract][Full Text] [Related]
19. IgG autoantibodies directed against desmoglein 3 cause dissociation of keratinocytes in canine pemphigus vulgaris and paraneoplastic pemphigus.
Nishifuji K; Olivry T; Ishii K; Iwasaki T; Amagai M
Vet Immunol Immunopathol; 2007 Jun; 117(3-4):209-21. PubMed ID: 17350107
[TBL] [Abstract][Full Text] [Related]
20. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
Pollmann R; Schmidt T; Eming R; Hertl M
Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
